The specific aims of this pragmatic randomized controlled trial are to compare initiating
injectable extended release naltrexone (XR-NTX) or oral naltrexone (PO-NTX) at the time of
discharge from a medical hospitalization for patients with alcohol use disorder (AUD) on: 1)
alcohol consumption and consequences, and 2) acute healthcare utilization (including hospital
readmission and emergency visits) and cost-effectiveness. In exploratory analyses, the
investigators will assess moderators of medication effects including demographic, behavioral,
and genetic factors.
Phase:
Phase 4
Details
Lead Sponsor:
Boston University
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)